Anti-Rb (Human) mAb

MBL
Product Code: MBL-MK-15-3
Product Group: Primary Antibodies
Supplier: MBL
CodeSizePrice
MBL-MK-15-3100 ug£323.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: IgG2a κ
Antibody Clonality: Monoclonal
Antibody Clone: 3H9
Regulatory Status: RUO
Target Species: Human
Applications:
  • Immunohistochemistry (IHC)
  • Immunoprecipitation (IP)
  • Western Blot (WB)
Shipping:
4°C
Storage:
-20°C

Images

1 / 1

Documents

Further Information

Applications:
WB - 5-10 ug/mL (chemiluminescence detection system) IP - 1-5 ug / 200-300 uL of cell extract IHC - 5 ug/mL (Heat treatment required for paraffin)
Background:
Mutation of the retinoblastoma tumor suppressor gene alone is sufficient to cause retinoblastoma in humans, suggesting that it might play a role in the normal coordination of cell proliferation and cell death. Deletion or mutational inactivation of the retinoblastoma tumor suppressor protein (Rb) is correlated with the genesis of a variety of human cancers including retinoblastoma, osteosarcoma, and carcinomas of the breast, bladder, and lung. Rb protein is phosphorylated by cyclinD-Cdk4/Cdk6 and cyclinA/cyclinE-Cdk2 during the G1/S transition. This phosphorylation causes the inactivation of the growth inhibitory functions of Rb. Rb undergoes phosphorylation and functional inactivation, permitting the cell to proceed into late G1.
Concentration:
1 mg/mL
Formulation:
100 ug IgG in 100 ul PBS containing 50% glycerol, pH 7.2. Contains no preservatives.
Gene IDs:
Human: 5925 Mouse: 19645
Immunogen Translated:
Recombinant human Rb (612-928 a.a.)
Reactivity:
This antibody reacts with human retinoblastoma gene product (110-115 kDa).
Shelf Life:
1 year
Source:
This antibody is precipitated from hybridoma (clone 3H9) supernatant using protein A Sepharose. This hybridoma was established by fusion of mouse myeloma cell P3U1 with Balb/c mouse splenocyte immunized with the recombinant human Rb protein corresponding to amino acids 612-928.
Target:
Rb

References

1) Lalande, M., et al. Cancer Genet.Cytogenet. 13, 283-295 (1984) 2) Lee, W. H., et al. Science, 235, 1394-1399 (1987) 3) Taya, Y., et al. Biochem. Biophys. Res. Commun. 164, 580-586 (1989) 4) Lin, B. T. Y., et al. EMBO J. 10, 857-864 (1991) 5) Wang, N.P., et al. Cell Growth Differ. 1, 233-239 (1990)